Skip to main content

NASDAQ:KTRA - Kintara Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 293.70 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.27
▼ -0.01 (-0.78%)
1 month | 3 months | 12 months
Get New Kintara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KTRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KTRA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.00
▲ +293.70% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Kintara Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $7.00 and a low forecast of $3.00. The average price target represents a 293.70% upside from the last price of $1.27.

Buy

The current consensus among 2 polled investment analysts is to buy stock in Kintara Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/3/2021AegisBoost Price TargetBuy$6.00 ➝ $7.00High
i
11/20/2020Maxim GroupInitiated CoverageBuy$3.00High
i
Rating by Jason McCarthy at Maxim Group
10/1/2020AegisReiterated RatingBuy$6.00High
i
9/14/2020AegisInitiated CoverageBuy$6.00High
i
7/28/2020Maxim GroupReiterated RatingBuy$2.00Medium
i
Rating by Naureen Quibria at Maxim Group
6/23/2020Maxim GroupInitiated CoverageBuy$2.00Medium
i
Rating by Naureen Quibria at Maxim Group
6/6/2020Maxim GroupInitiated CoverageBuy$2.00High
i
Rating by Jason McCarthy at Maxim Group
5/14/2020Maxim GroupReiterated RatingBuy$2.00Low
i
11/15/2019Maxim GroupReiterated RatingBuyLow
i
Rating by Jason McCarthy at Maxim Group
9/6/2019Maxim GroupInitiated CoverageBuyHigh
i
7/11/2019Dawson JamesReiterated RatingBuyHigh
i
Rating by J. Kolbert at Dawson James
5/23/2018HC WainwrightSet Price TargetBuy$120.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
1/4/2018HC WainwrightSet Price TargetBuy$120.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
11/29/2017HC WainwrightSet Price TargetBuy$120.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/16/2017HC WainwrightSet Price TargetBuy$120.00N/A
i
Rating by R. Selvaraju at HC Wainwright
10/5/2017HC WainwrightReiterated RatingBuy$120.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
9/11/2017Maxim GroupReiterated RatingHoldHigh
i
Rating by Jason McCarthy at Maxim Group
8/14/2017Maxim GroupDowngradeBuy ➝ HoldLow
i
Rating by Jason McCarthy at Maxim Group
8/8/2017Dawson JamesReiterated RatingBuyHigh
i
Rating by R. Wasserman at Dawson James
6/24/2017HC WainwrightSet Price TargetBuy$120.00Low
i
Rating by Ram Selvaraju at HC Wainwright
6/23/2017Maxim GroupReiterated RatingBuy$110.00Low
i
Rating by Jason McCarthy at Maxim Group
5/30/2017HC WainwrightReiterated RatingBuy$120.00Medium
i
5/25/2017Maxim GroupSet Price TargetBuy$110.00Medium
i
Rating by Jason McCarthy at Maxim Group
4/13/2017Maxim GroupSet Price TargetBuy$110.00High
i
Rating by Jason McCarthy at Maxim Group
4/5/2017Maxim GroupReiterated RatingBuy$110.00Low
i
Rating by Jason McCarthy at Maxim Group
1/26/2017Maxim GroupReiterated RatingBuy$110.00N/A
i
1/5/2017AegisInitiated CoverageBuy$160.00N/A
i
9/12/2016HC WainwrightReiterated RatingBuy$120.00N/A
i
7/18/2016Rodman & RenshawReiterated RatingBuyN/A
i
5/24/2016Rodman & RenshawReiterated RatingBuyN/A
i
(Data available from 5/18/2016 forward)
Kintara Therapeutics logo
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.27
$1.27
$1.27

50 Day Range

MA: $1.43
$1.26
$1.86

52 Week Range

Now: $1.27
$0.61
$3.35

Volume

200 shs

Average Volume

831,411 shs

Market Capitalization

$41.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Kintara Therapeutics?

The following Wall Street sell-side analysts have issued reports on Kintara Therapeutics in the last twelve months: Aegis, and Maxim Group.
View the latest analyst ratings for KTRA.

What is the current price target for Kintara Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Kintara Therapeutics in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 293.7%. Aegis has the highest price target set, predicting KTRA will reach $7.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for Kintara Therapeutics in the next year.
View the latest price targets for KTRA.

What is the current consensus analyst rating for Kintara Therapeutics?

Kintara Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KTRA will outperform the market and that investors should add to their positions of Kintara Therapeutics.
View the latest ratings for KTRA.

What other companies compete with Kintara Therapeutics?

How do I contact Kintara Therapeutics' investor relations team?

Kintara Therapeutics' physical mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The company's listed phone number is 858 350 4364 and its investor relations email address is [email protected] The official website for Kintara Therapeutics is www.kintara.com.